Key Takeaways:
- FDA approved Novo Nordisk's oral Wegovy on December 22, 2025—the first oral GLP-1 medication approved specifically for weight loss
- Launches January 2026 with self-pay pricing starting at $149/month, making it more affordable than injectable alternatives
- Clinical trials showed 16.6% average weight loss, matching the effectiveness of weekly Wegovy injections
Historic FDA Approval Changes Weight Loss Treatment
The FDA approved Novo Nordisk's oral Wegovy (once-daily semaglutide 25mg) on December 22, 2025, making it the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management. This approval represents a watershed moment for people seeking weight loss treatment, eliminating the need for weekly injections that have been the standard for GLP-1 medications.
Novo Nordisk expects to launch the Wegovy pill in early January 2026, with manufacturing already underway at the company's North Carolina facilities. The company will offer oral Wegovy starting at $149 for a month-long supply without insurance, with insurance co-pays potentially as low as $25 or less.
Matching Injectable Results with Daily Convenience
The approval was based on robust clinical trial data that showed impressive weight loss results. In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated 16.6% mean weight loss when treatment was adhered to in adult participants with obesity or overweight with one or more comorbidities. The weight loss achieved with the Wegovy pill is similar to that of injectable Wegovy 2.4 mg.
Oral semaglutide 25 mg achieved 16.6% mean weight loss at 64 weeks with full adherence, compared with 2.7% for placebo. One-third of adherent participants achieved at least 20% weight loss, versus under 3% with placebo. Even when accounting for people who stopped treatment early, weight loss remained robust in the treatment-policy analysis, at 13.6% versus 2.2% with placebo.
A New Era of Accessible GLP-1 Treatment
The oral formulation addresses several barriers that have limited access to GLP-1 medications. The newly approved oral form of Novo's drug could be preferable for people who dislike injections and eliminates the need for a cold chain and refrigeration of the final product.
Both the oral and injectable Wegovy contain semaglutide, but the oral Wegovy pill will be available in starting doses of 1.5 mg, whereas the injectables are available in 2.4 mg doses. The oral Wegovy pill also requires a 30-minute waiting period after consumption before eating. Injectable forms of Wegovy must be stored in a refrigerator between 36 and 46 degrees Fahrenheit. Pill forms of Wegovy don't require refrigeration.
The convenience factor extends beyond storage. Many people have avoided GLP-1 treatment due to needle anxiety or concerns about administering weekly injections. This oral option removes those barriers while delivering comparable weight loss results.
Competitive Landscape and Market Impact
Lilly's own oral GLP-1, orforglipron, was approved on April 1, 2026 as Foundayo, the first oral GLP-1 pill cleared via the FDA's Commissioner's National Priority Voucher pathway. In its phase 3 ATTAIN-1 study, the highest dose of once-daily orforglipron at 36 mg produced 12.4% average weight loss at 72 weeks.
However, Novo Nordisk has gained first-mover advantage in the oral GLP-1 space for weight loss. "Now, with Wegovy pill, we are offering a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in Phase III trials," said Dave Moore, Novo Nordisk's executive vice president for U.S. operations.
This competition will likely drive innovation and potentially lower costs across the oral GLP-1 market, benefiting people seeking these treatments.
Safety Profile Remains Consistent
The well-known safety and tolerability profile of semaglutide was reaffirmed with the Wegovy pill in the OASIS-4 trial, which was comparable to previous trials with semaglutide for weight management. The trial showed people who took the pill experienced similar side effects as those on injectables, including gastrointestinal issues such as nausea, diarrhea and vomiting.
Most side effects were mild to moderate and decreased over time as participants' bodies adjusted to the medication. The oral formulation doesn't introduce new safety concerns beyond what's already known about semaglutide.
What This Means for You
This historic approval opens new possibilities for people who have been hesitant to start GLP-1 treatment due to injection anxiety or storage requirements. The oral Wegovy pill offers the same proven weight loss results as the injectable version but in a convenient daily tablet that doesn't require refrigeration.
At $149 per month for self-pay, the oral version provides a more accessible entry point compared to brand-name injectable GLP-1s that can cost over $1,000 monthly without insurance. If you're considering GLP-1 treatment but have concerns about injections, this new option could be the solution you've been waiting for. You can compare costs and explore whether oral Wegovy fits your budget and treatment goals.
With Eli Lilly's orforglipron now approved as Foundayo, you have more oral GLP-1 options than ever before. Consider speaking with healthcare providers through telehealth platforms to discuss whether oral GLP-1 treatment aligns with your weight loss goals and medical history. Many telehealth providers can prescribe these medications and help you navigate insurance coverage options.
Sources
- Novo Nordisk: FDA Approves the Wegovy Pill, the First Oral GLP-1 for Weight Loss - FDA approval, December 22, 2025
- CNBC: FDA approves first GLP-1 pill for obesity from Novo Nordisk - Approval coverage
- Fierce Pharma: Novo's Wegovy pill makes US debut at $149/month - January 2026 launch and pricing
- Applied Clinical Trials: FDA Approves Oral Wegovy, Positive OASIS Trial Results - OASIS-4 16.6% data